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INTRODUCTION
Over the past 30 years, the introduction of preoperative 
chemoradiotherapy (CRT), advances in surgical techniques, 
and new imaging modalities for selecting treatment and 
surgical planning have resulted in dramatic improvements 
in local recurrence rates and quality of life in patients with 
rectal cancer. In this context, baseline magnetic resonance 
imaging (MRI) in patients with locally advanced rectal 
cancer (LARC) has an undeniable role in the determination 
of neoadjuvant CRT through risk stratification by the 
evaluation of circumferential resection margin (CRM), 
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T3 sub-classifications, and assessment of extramural 
vessel invasion, nodal status, and sphincter invasion (1). 
Therefore, there is a uniform consensus on the value of 
baseline MRI in the preoperative evaluation for patients 
with rectal cancer (2). After CRT, most LARCs demonstrate 
variable degrees of tumor response, including pathologic 
complete remission (pCR) in 4–31% of patients (3). Patients 
with complete remission (CR) by CRT can achieve excellent 
local tumor control and a better quality of life with organ-
preserving treatments such as local excision or even watch-
and-wait management (4). Therefore, an evaluation of 
tumor responses may become a key factor in determining 
the treatment strategies for individual patient after CRT.
Post-CRT MRI is also considered to be the first choice 
for evaluating treatment response after CRT. However, 
whether post-CRT MRI evaluation for tumor response 
can inform treatment strategies remains controversial. 
Surgeons are often reluctant to deviate from initial plans 
because of concerns about residual viable tumor cells in 
the rectal wall or the mesorectal nodes, even in patients 
with clinical complete response (cCR) after preoperative 
CRT (5). Furthermore, the diagnostic outcomes and clinical 
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impacts of post-CRT MRI have not been satisfactory for 
deciding the more radical surgical dissection or the organ-
preserving strategy because of insufficient reliability for 
differentiating residual tumors from CRT-related changes 
such as edema, necrosis, and particularly fibrotic change 
after CRT. Therefore, radiologists should be aware that their 
interpretation might result in a faulty decision for organ-
preserving treatment or conversely unnecessary radical 
surgery which compromises patients’ quality of life.
In this review, we will introduce recent advances in 
the treatment of LARC and describe the role of post-CRT 
MRI in the clinical restaging of rectal cancer after CRT 
concerning improving local control and patient quality of 
life. Finally, we will discuss the issues faced by radiologists 
in determining tumor response after CRT.
Treatment Options after Chemoradiotherpy for 
Locally Advanced Rectal Cancers
Total mesorectal excision (TME) is the standard treatment 
for the majority of patients who underwent CRT for rectal 
cancer. It emphasizes en-bloc resection of the mesorectum 
which refers to the fatty tissue envelope of the rectum, 
containing blood and lymphatic vessels (6). TME can 
be performed as a component of low anterior resection 
(LAR) or abdominoperineal excision (APE) procedures. 
The decision to perform either LAR or APE is based on 
the tumor location in relation to the anal sphincter 
complex. LAR is any sphincter-preserving resection with 
anastomosis beneath the anterior peritoneal reflection. LAR 
can be further divided into LAR and ultra-LAR including 
intersphincteric resection based on the level of dissection 
and anastomosis (above or below the mesorectal end, 
respectively) (7). While LAR is performed for tumors that 
are distant from the anal sphincter, APE is defined as an en-
bloc removal of a tumor with the anal sphincter and anus, 
accompanying a permanent colostomy (Table 1, Fig. 1) and 
is usually performed for tumors that are near to or involve 
the anal sphincter (intersphincteric plane or external 
sphincter involvement). Therefore, the distance between 
the distal end of the tumor and anorectal junction should 
be provided in the post-CRT MRI evaluation. In the era of 
neoadjuvant CRT, distal surgical margin even ≤ 1 cm appear 
sufficient (8). Anatomically, there is no mesorectal fat up 
to approximately 1 cm above the anorectal junction (upper 
end of intersphincteric plane) (Fig. 2) (9). Treatment failure 
is common at this level because the tumor penetrating 
the muscle proper directly abuts levator ani muscle 
without intervening mesorectal fat (10, 11). Therefore, 
the information about whether the distal level of a tumor 
is located above or below the level of the mesorectal end 
(approximately upper end of intersphincteric plane) 1 cm 
above the anorectal junction is important for determining 
the salvage of anal sphincter. 
APE can be classified into traditional APE or extralevator 
abdominoperineal excision (ELAPE) (Fig. 1). Unlike 
traditional APE, because ELAPE includes the en-bloc 
removal of the levator muscles, ELAPE is considered 
to be a more radical approach and thus increases CRM 
clearance, particularly in patients whose levator plane is 
still threatened on post-CRT MRI (Figs. 1, 3) (12). For T4b 
tumors which invade other organs such as urinary bladder, 
prostate, uterus, or sacrum, pelvic exenteration can be 
performed (13).
Recently, organ-preserving strategies have also been 
deployed to avoid rectal excision in patients in whom 
complete tumor shrinkage without residual tumor tissue has 
been identified after neoadjuvant CRT. These strategies are 
Table 1. Relevant Post-CRT MRI Findings according to Type of Surgery
Type of Surgery Relevant Post-CRT MRI Findings 
Low anterior or sphincter-saving resection
- Distal margin of treated tumor above 1 cm line above anorectal junction
- Intact anal sphincter integrity
APE or intersphincteric resection* - Distal margin of treated tumor below 1 cm line above anorectal junction
APE - Intersphincteric space or external sphincter involvement
Extralevator abdominoperineal excision - Levator ani muscle plane threatening (< 1–2 mm) or invasion
Pelvic exenteration - Adjacent organ invasion
Local excision
- Treated tumor confined to rectal wall without extramural tumor infiltration (ycT1)
- ycN0 
Selective pelvic lymph node dissection - Enlarged lymph nodes > 5 mm in short axis at lateral pelvic side walls 
*Intersphincteric resection can be performed in cases of no tumor involvement in intersphincteric space or external sphincter. APE = 
abdominoperineal excision, CRT = chemoradiotherapy, MRI = magnetic resonance imaging
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divided into local excision and watch-and-wait strategy. 
Patients showing clinical downstaging to cT0-1N0 after 
CRT may be candidates for local excision. Local excision 
procedures include transanal excision (TAE), transanal 
endoscopic microsurgery (TEM), and transanal minimally 
invasive surgery (TAMIS) (14). TAE is indicated for tumors 
that lie below the level of peritoneal reflection. TEM 
or TAMIS are performed for tumors that lie above the 
peritoneal reflection. With these local excision techniques, 
resection of full tissue layers including mucosa, submucosa, 
and muscle proper can be performed. However, the complete 
dissection of the lymph nodes is impossible. Therefore, 
careful evaluation to guarantee the absence of extramural 
tumor infiltration and residual metastatic lymph node on 
post-CRT MRI is crucial for oncologic safety.
Surgical planning should be conducted to accurately assess 
the extent of the local tumor and the relationship between 
residual tumors and the anal sphincter on post-CRT MRI. 
However, distinguishing residual viable tumors from fibrotic 
changes following CRT is often challenging on post-CRT 
Fig. 1. Traditional APE and extralevator APE. 
A. Traditional APE: Dotted line indicates dissection plane. Because levator muscle is not included in surgical specimen, it is appropriate for 
tumors without threatening to levator muscle plane. B. Extralevator APE: Tumor infiltration extends to left levator ani muscle. Levators are 
removed in this surgical specimen. This type of surgery is mandatory for lower rectal cancer with levator involvement to achieve negative pCRM. 
APE = abdominoperineal excision, pCRM = pathologic circumferential resection margin
A B
Fig. 2. Mesorectal fat bare area between distal end of mesorectum (black line) and level of anorectal junction (red line). 
A. Schematic drawing depicting mesorectal fat bare area. Length of bi-directional arrow is approximately 1 cm. B. Cadaveric dissection image 
shows that mesorectal fat is absent along longitudinal extent corresponding to same bi-directional arrow. At this site, only rectal wall is present. 
(Adapted from Kim. Yonsei Med J 2005;46:737-749) (73). C. On T2-weighted oblique coronal image, imaginary black line is drawn at 1 cm (bi-
directional arrow) above anorectal junction level (red line) which roughly corresponds to upper end of intersphincteric plane.
BA C
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MRI. Although fibrotic changes appear as decreased signal 
intensity (SI) on T2-weighted images, even the dense dark 
fibrotic tissue on MRI could have microscopic viable residual 
cancer cells. The possibility of a viable residual tumor in 
the dark fibrotic tissue is known to be approximately 50% 
(15). Determining tumor relationships with the surrounding 
structures (e.g., the anal sphincter) on the basis of T2 SI 
changes only according to the hypothesis that only the 
intermediate T2 SI portion within the treated mass is viable 
cancer and the dark SI portion is exclusively fibrotic change, 
may jeopardize oncologic safety (Fig. 3). Furthermore, the 
relationship between tumors and surrounding organs or 
sphincters on post-CRT MRI should be determined on the 
basis of the whole treated tumor including any fibrotic 
tissues, except for fibrotic spiculations. The possibility of 
residual cancer cells within the fibrotic spiculation on post-
CRT MRI is known to be extremely rare (16). 
Timing of MRI for Evaluation of Treatment 
Response after Chemoradiotherapy
The optimal timing of post-CRT MRI for the evaluation 
of tumor response depends on the timing of surgery after 
CRT. However, surgical timing with respect to CRT varies 
Fig. 3. Distal rectal cancer with left levator ani muscle involvement. 
A. On baseline MRI, ulceroinfiltrative mass is observed in distal rectum with tumor infiltration into left levator ani muscle (arrow). B. On post-
CRT MRI, signal drop is seen within entire tumor. However, shrunken tumor still invades levator muscle (arrow). Traditional APE was performed. 
Histopathology revealed tumors with pathologic tumor regression grade 3 and positive pCRM (not shown). C. Follow-up CT 6 months after 
operation shows recurrent mass at remnant left levator muscle (arrows). CRT = chemoradiotherapy, MRI = magnetic resonance imaging
A B C
Fig. 4. Progressive tumoricidal effect and fibrotic change in rectal cancer after routine timing window. 
A. On baseline MRI, semi-circular mass with intermediate SI is noted at left lateral wall of rectum (curved line indicates circumferential tumor 
extent). B. Post-CRT MRI obtained at four weeks after completion of CRT shows increased proportion of fibrotic change as well as decreased 
proportion of tumor SI, indicating tumor regression. Patient refused surgical option at that time. C. On post-CRT MRI obtained at 22 weeks, 
proportion of fibrotic change is further increased with decreased circumferential tumoral extent. Histopathology after subsequent APE revealed 
ypT2 (not shown). SI= signal intensity
A B C
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due to a lack of consensus on the optimal interval. Because 
tumoricidal effects of CRT increase over time (Fig. 4), it is 
possible that more cases achieving pCR would be identified 
with a longer waiting time after CRT (17). However, 
because surgeons are reluctant to delay operation beyond 
eight weeks due to concerns about radiation-induced 
pelvic fibrosis and related surgical complications, surgery 
is generally performed at approximately 6–8 weeks after 
the completion of CRT (18), although delaying surgery 
more than eight weeks after completion of CRT may be 
more beneficial (19). Therefore, post-CRT MRI should be 
performed 6–8 weeks after the termination of CRT, and 
immediately before surgery.
Reported Items on Post-Chemoradiotherapy 
MRI 
After neoadjuvant treatment, reports of rectal MRI should 
include the following items: local tumor status, mesorectal 
fascia (MRF) involvement, lymph node involvement, and 
extramural venous invasion (EMVI) status (20). 
Local Tumor Status
Accurate preoperative assessment of local tumor status 
following CRT is essential for deciding an appropriate 
treatment strategy. Tumor response after CRT can be 
evaluated by assessing MRI-based tumor regression 
grade (mrTRG) using an established scoring system and 
post-treatment T staging (ymrT) (21). Scoring systems 
established by the Magnetic Resonance Imaging and Rectal 
Cancer European Equivalence Study (MERCURY) study group 
and the European Society of Gastrointestinal and Abdominal 
Radiology (ESGAR) are mostly similar but differ most 
notably in their definitions of good responders (Table 2, 
Fig. 5) (20-22). mrTRG scores developed by the MERCURY 
study group were derived from pathologic TRG (pTRG). 
mrTRG was defined according to whether fibrous or tumor SI 
predominates within the entire tumor (23). In other words, 
mrTRG is determined by the proportion of presumed residual 
tumor and fibrotic change on T2-weighted images. On post-
CRT T2-weighted imaging, the fibrotic portion shows dark 
SI similar to that of the muscularis propria, whereas the 
portion of the residual tumor shows intermediate SI similar 
to that of baseline tumor (24). mrTRG scoring system and 
the definition of TRG 1–2 have been changed between 
2012 and 2016 (20). Grade 1 now indicates a complete 
radiologic response with a linear/crescentic 1–2 mm scar 
in the mucosa or submucosa on MRI (Fig. 5B). Grade 2 is 
indicated by a good response and MRI findings include 
dense fibrosis without obvious residual tumor, suggesting 
minimal residual disease or no tumor (Fig. 5C). Grade 3 is 
indicated by a moderate response, with more than 50% of 
areas with fibrosis/mucin and visible intermediate tumor 
signal on MRI (Fig. 5D). Grade 4 suggests a slight response 
to treatment, with MRI findings of few areas with fibrosis/
mucin and mostly tumor-derived MRI signal (Fig. 5E). 
Grade 5 indicates no response to therapy, showing a similar 
tumor to the baseline or significant tumor regrowth. These 
mrTRG scores have significant implications for clinical care 
and outcomes. According to a previous study, disease-free 
survival and overall survival differed significantly between 
mrTRG 1–3 (good response) and mrTRG 4–5 (poor response) 
(25). Recently, the definition of good responder has been 
evolved in mrTRG scoring system due to an introduction 
of organ-preserving approach. It requires a higher positive 
predictive value (PPV) for pCR or near-pCR. Therefore, recent 
Table 2. MRI-Based Tumor Regression Grade
Grade Response MERCURY (2012) MERCURY (2016) ESGAR (2016)
mrTRG 1
Complete
  response
No evidence of tumor SI or 
  fibrosis only
Linear/crescentic 1–2 mm scar
  in mucosa or submucosa only
Completely normalized 
  rectal wall
mrTRG 2
Good 
  response
Dense hypointense fibrosis 
  with minimal residual tumor
No obvious residual tumor, 
  signifying minimal residual disease 
  or no tumor
Fibrotic wall thickening 
  without clear mass
mrTRG 3
Moderate 
  response
> 50% fibrosis/mucin and visible 
  tumor with intermediate SI
> 50% fibrosis/mucin and visible 
  tumor with intermediate SI
Residual mass (and/or 
  focal high SI on DWI)
mrTRG 4
Slight 
  response
Little areas of fibrosis/mucin, 
  but mostly tumor
Little areas of fibrosis/mucin, 
  but mostly tumor
mrTRG 5
No 
  response
Intermediate SI, same appearances
  as original tumor/tumor regrowth
Intermediate SI, same appearances 
  as original tumor/tumor regrowth
DWI = diffusion-weighted imaging, ESGAR = European Society of Gastrointestinal and Abdominal Radiology, MERCURY = Magnetic 
Resonance Imaging and Rectal Cancer European Equivalence Study, mrTRG = MRI-based tumor regression grade, SI = signal intensity
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reports suggest only mrTRG 1 and 2 as good responders or 
candidates for organ-preserving treatments (26, 27).
Different from a 5-point mrTRG scoring system, ESGAR 
consensus meetings have suggested a three-stage 
classification: completely normalized wall, fibrotic wall 
thickening only, and residual mass. They proposed that an 
identification of a normalized two-layered wall after CRT 
is suggestive of CR on T2-weighted imaging (Fig. 5A) and 
Fig. 5. Post-CRT mrTRG system. 
A. ESGAR-based complete response: completely normalized rectal wall in initial tumor site (arrow). B. mrTRG 1: linear/crescentic scar in mucosa/
submucosal layer (arrow) which corresponds to ESGAR-based fibrotic wall thickening without clear mass. C. mrTRG 2: dense fibrotic transmural 
mass without intermediate tumor SI (arrow) which also corresponds to ESGAR-based fibrotic wall thickening without clear mass. D. mrTRG 3: 
more than 50% of areas with fibrosis and visible intermediate tumor (arrows) which corresponds to residual mass on ESGAR-based grading. E. 
mrTRG 4: few areas with fibrosis and mostly intermediate tumor SI (arrows) which also corresponds to residual mass on ESGAR-based grading. 
ESGAR = European Society of Gastrointestinal and Abdominal Radiology, mrTRG = MRI-based tumor regression grade
A
D
B
E
C
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fibrotic residue without an isointense mass may indicate 
CR or near-CR (Fig. 5B, C). However, the item related to a 
normalization of the rectal wall is not included in mrTRG 
scoring system proposed by MERCURY group. Therefore, the 
actual threshold for defining radiologic CR is somewhat 
different between the two scoring systems. Considering 
that complete normalization of the rectal wall after CRT is 
extremely rare in clinical practice, ESGAR group seems to 
take a stricter position in defining radiologic CR. 
Local tumor status can also be assessed by post-treatment 
T staging (ymrT). On post-CRT MRI, yT stage can be defined 
as yT1–2, yT3, and yT4. yT3 can be further divided into 
yT3a or 3b with ≤5 mm extramural tumor depth and yT3c or 
3d with > 5 mm extramural tumor depth. yT4 is designated 
when the tumor invades into the visceral peritoneum 
or adjacent organs/structures (Fig. 6). Reported overall 
sensitivity of T2-weighted imaging in a meta-analysis is 
unsatisfactory (approximately 50%) (28). Overstaging 
is the main source of staging error because CRT-induced 
fibrotic change at the interface between the tumor and 
the mesorectal fat can usually be mis-interpreted as viable 
tumor. The meta-analysis also revealed that restaging 
with diffusion-weighted imaging (DWI) demonstrated an 
improved mean sensitivity without a decrease of specificity. 
Therefore, DWI may be the solution for overcoming such 
overstaging issue (Fig. 7). 
For tumors located in the far distal rectum, it is 
important to evaluate the relationship between the tumor 
Fig. 6. MRI-based T staging after CRT (ymrT) for rectal cancer. 
A. Post-CRT MRI demonstrates localized transmural rectal wall thickening (ymrT1 or 2) with smooth outer margin (arrows). ypT2 was 
pathologically confirmed (not shown). B. Post-CRT MRI demonstrates circumferential mass (arrow) with irregular outer margin (ymrT3) within 
mesorectum. ypT3 was identified on histopathology (not shown). C. Post-CRT MRI reveals annular mass in lower rectum with posterior vagina 
infiltration (arrow) by tumor with intermediate SI (ymrT4b). After surgery, ypT4b was confirmed (not shown).
A B C
Fig. 7. Limitation of qualitative evaluation based on SI of anatomical T2-weighted imaging for tumor response evaluation. 
A. Baseline T2-weighted image (left) shows bulky mass with MRF involvement at 8 o’clock direction (arrow). DWI (right) demonstrates strong 
diffusion restriction within whole tumor area (arrow). B. On post-CRT T2-weighted image (left), intermixed SI of tumor and fibrosis at initial 
tumor site (arrow) is noted. Therefore, mrTRG 3 was reported. CRM involvement by treated tumor is still suspected at same direction (arrow) 
because CRM threatening is determined by whole treated tumor including fibrotic component on post-CRT MRI interpretation. On DWI (right), 
however, no diffusion restriction is seen in entire tumor area (arrow). Pathologic complete response was confirmed after TME (not shown). CRM = 
circumferential resection margin, DWI = diffusion-weighted imaging, MRF = mesorectal fascia, TME = total mesorectal excision
A B
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and anal sphincter complex, particularly when deciding 
whether sphincter-saving surgery is possible or not (20). 
In such cases, a precise description regarding the relevant 
anatomical relationships may provide more valuable 
information than ymrT stage alone. Following findings are 
usually recommended to be described for lower tumors near 
the anal sphincter complex: 1) distal margin of the tumor 
whether it is located at above or below from the line 1 cm 
above the anorectal junction, 2) sphincter involvement by 
the tumor whether the tumor invades only to the internal 
sphincter muscle or extends to the intersphincteric fat 
plane/external sphincter muscle, and 3) involvement of 
levator ani muscle. The line 1 cm above the anorectal 
junction (black line in Fig. 3A) is approximately identical 
to an upper margin of the intersphincteric plane where 
is vulnerable to levator threatening (9, 10). Therefore, it 
is important to report the relationship between this line 
and distal margin of the tumor. For lower rectal cancers 
that threaten the levator ani muscle or involve the 
intersphincteric plane/external sphincter muscle, sphincter-
saving surgery is not feasible. However, if the tumor shows 
a favorable response such as mrTRG 1 or 2 after CRT and 
no extramural tumor spread such as nodal metastasis is 
present on post-CRT MRI, organ-preserving surgery such as 
intersphincteric resection or TAE may be considered (26).
Circumferential Resection Margin Involvement
Pathologic circumferential resection margin (pCRM) is 
one of the key components for the determination of local 
tumor recurrence in patients who undergo TME with or 
without preoperative CRT (25, 29). Prospective trials have 
reported a local recurrence rate of 25–26% after CRT in 
patients with pCRM involvement (25, 30). The definition 
of positive pCRM in most studies is the presence of tumor 
cells within 1 mm from resection margin (31). On baseline 
MRI, when the shortest distance between the tumor 
and MRF is ≤ 1–2 mm, potential CRM is considered to be 
threatened or involved. However, an interpretation of MRF 
involvement after CRT is problematic because hypointense 
fibrotic change frequently remains at the initial tumor area 
(Fig. 7). Such limitations result in a low PPV (44–57%) 
and high negative predictive value (NPV) (91–100%) of 
post-CRT MRI for positive pCRM (16, 32, 33) with an area 
under the receiver operating characteristic curve (AUC) of 
0.73–0.89 (16, 34, 35). Although high NPV of post-CRT 
MRI may guarantee the oncologic safety after TME, low 
PPV prevents the decision for performing more aggressive 
or additional treatments. To overcome this issue, a few 
groups have suggested specific morphologic patterns on 
MRI for determining MRF involvement after CRT in addition 
to applying the distance from MRF (1–2 mm) (16, 34). 
Specifically, if MRF infiltration/penetration by fibrotic or 
tumor tissue is present along with fibrotic thickening of 
MRF itself, a higher risk of pCRM involvement after CRT is 
suggested compared to MRF threatening only by spiculated 
fibrotic change or treated tumor without thickening of 
MRF itself (Fig. 8). Some investigators have also reported 
the potential value of DWI to predict tumor clearance at 
the MRF after CRT (36). In this study, the PPV for MRF 
involvement was significantly higher with combined T2-
weighted imaging and DWI (82–91%) than with T2-
weighted imaging alone (30–45%) (p ≤ 0.025) (36). If 
high-risk patients with positive pCRM even after CRT can be 
accurately selected, an evidence for introducing additional 
treatment options such as extramesorectal excision or 
multivisceral resection, boost radiotherapy at the site of 
MRF invasion, or upfront chemotherapy may be provided in 
these highly selected patients.
Lymph Node Involvement
Considering local excision may be a suitable option for 
patients with good tumor response to CRT without residual 
positive lymph nodes, radiologic nodal restaging after CRT 
is crucial for the assessment of these patients. MRI criteria 
used to determine lymph node involvement may differ 
between before and after CRT. Before CRT, morphologic 
findings such as border irregularities and heterogeneous 
SIs are better predictors than the size of lymph nodes (37). 
On the other hand, after CRT, these morphologic criteria 
were found to be unreliable predictors for determining 
malignant nodes (38, 39). Moreover, decreased nodal size 
(e.g., < 3 mm) after CRT can limit the evaluation of these 
morphological features; thus the size criteria (e.g., a short 
axis > 5 mm) may be more reliable. 
Previous studies have indicated that size measurement 
after CRT shows better performance with an AUC of 0.85–
0.90 than primary staging (AUC = 0.75) (40, 41). A possible 
explanation for such better performance of size criteria after 
CRT is that the size and number of lymph nodes harvested 
after CRT are reduced (42, 43), decreasing the potential for 
interpretation errors in the remaining small lymph nodes. 
On histology, many lymph nodes after CRT reveal fibrous 
capsular thickening and sclerosis within the medulla (44). 
In addition, radiologists should be aware that a decrease in 
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size of nodes after CRT cannot always guarantee malignant 
nodes because benign as well as malignant nodes can show 
decrease in size after CRT (43, 44) (Fig. 9).
In lateral pelvic lymph nodes, the same size criteria 
(a short axis > 5 mm) can be used to reliably identify 
malignant nodes after CRT (45, 46) (Fig. 10). Persistently 
enlarged lateral pelvic nodes > 5 mm on post-CRT MRI are 
significantly associated with residual nodal metastasis 
and the size of lateral pelvic node on post-CRT MRI is an 
independent predictor for lymph node metastasis (46). 
Therefore, the decision of selective lateral pelvic node 
dissection should be made on the basis of nodal response 
to CRT (e.g., via size of lateral pelvic node on post-CRT 
MRI) (Table 1) (45, 46). For patients with responsive lateral 
Fig. 8. Tumor penetration through MRF with MRF thickening which suggests high risk for positive pCRM even after completion of 
CRT. 
A. Post-CRT MRI shows circumferential mass with intermediate SI. Tumor penetration to MRF with MRF thickening (arrow) is noted. Pathologic 
result after TME was positive pCRM (not shown). B. In another patient, post-CRT MRI still demonstrates tumor infiltration anteriorly into prostatic 
gland (arrow). After APE with partial prostatectomy, pCRM was found to be positive. C. On post-CRT MRI in another patient, tumor with anterior 
MRF threatening by spicules of treated tumor (arrow) is noted. However, MRF thickening or penetration is not demonstrated (arrow). Pathologic 
result after TME was negative pCRM (not shown).
A B C
Fig. 9. Tumor response of lymph node after CRT. 
A. On baseline MRI, suspicious metastatic node with short axis diameter of 9 mm is seen at right lateral pelvic side wall (arrow). B. Post-CRT MRI 
reveals interval decrease of node (arrow) and size is less than 5 mm. Lymph node dissection at right lateral pelvic side wall was performed. Viable 
tumor cells were not found in dissected lymph nodes (not shown). However, pathologic nodal status after CRT still remains uncertain because 
both normal and metastatic lymph nodes show interval decrease in size after CRT. 
A B
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pelvic nodes (short axis < 5 mm) after CRT, lateral pelvic 
node dissection may not be necessary although there has 
been still a debate on this issue. 
Extramural Venous Invasion
EMVI is pathologically defined when tumor cells invading 
the veins beyond the outer walls of the muscularis propria 
are present (47). After CRT, EMVI can be assessed either by 
histopathology (ypEMVI) or by MRI (ymrEMVI). ymrEMVI is 
defined as positive when minimal or less than 25% fibrotic 
change is detected on treated tumor component within the 
extramural venous structure (Fig. 11) (48, 49). 
Lee et al. (48) reported that the diagnostic performance 
of MRI for determining EMVI after CRT was comparable 
to that on pre-CRT MRI (AUC, 0.830 versus 0.778, p = 
0.076) when using the same scoring system for mrEMVI. 
According to another study by Chand et al. (47), positive 
EMVI after CRT was more frequently detected on MRI than 
on histopathology (53% versus 19%) and both ymrEMVI 
(hazard ratio 1.97) and ypEMVI (hazard ratio 2.39) were 
significant predictors for decreased survival. Considering the 
advantages of MRI such as multiplanar imaging capability 
and visualization of the entire rectum (50), radiation-
induced fibrosis and destruction of venous endothelium 
after CRT may be responsible for a higher false-negative 
rate of EMVI on histopathology (51). As persistent ymrEMVI 
after CRT may increase the risks of metastatic disease, it 
is an independent negative prognostic marker for disease-
free survival and implicit potential benefits of adjuvant 
chemotherapy (47).
Determining Complete Response on Post-
Chemoradiotherapy MRI
Most LARCs show variable tumor response, including 
pCR in up to 33% of patients (21, 52). Patients who 
achieved CR after CRT may potentially achieve excellent 
local tumor control and superior quality of life with organ-
preservation strategies such as local excision or even a 
watch-and-wait approach (53-55). If patients who have 
achieved pCR after CRT can be accurately identified before 
surgery, organ-preservation treatment strategies might be 
considered as an option in those selective patients. By 
avoiding radical surgery in these patients, the need for 
a permanent stoma may be avoided (53-55). However, if 
an inaccurate assessment for pCR status was made, the 
patients may lose the chance of standard radical TME 
surgery. Resultantly, oncologic safety of those patients 
may be severely jeopardized. Consequently, an increasing 
interest in organ-saving treatments can be met only if a 
reliable method to identify pCR is developed (56, 57). In 
reality, however, an accurate identification and prediction 
Fig. 10. Metastatic lymph nodes after CRT. 
A. Post-CRT MRI reveals persistently enlarged lymph node (arrow) with short axis diameter of 16 mm in right obturator area. Selective lymph 
node dissection at right pelvic side wall is performed and lymph node metastasis is pathologically confirmed (not shown). B. In another patient, 
post-CRT MRI demonstrates persistently enlarged node (arrow) with short axis diameter of 7.5 mm within mesorectum. After TME, metastasis is 
also identified within lymph node (not shown).
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of pCR is still challenging, as a reliable and non-invasive 
method is not yet fully available (58). Limited ability 
of post-CRT MRI to predict pCR also leaves a gap in the 
clinical process of determining a reasonable treatment 
strategy. The ideal balance between the sensitivity and 
specificity of MRI for the prediction of pCR is an ongoing 
issue of debate. Considering that a false-positive prediction 
of pCR can lead to an inappropriate use of organ-preserving 
treatments, potentially resulting in devastating outcomes, a 
conservative decision for cCR should be made to maximize 
the PPV of post-CRT MRI for the prediction of pCR when the 
results are equivocal.
Recently, a large-scale registry study investigated the 
clinical outcomes of patients with cCR, reporting a 2-year 
cumulative local regrowth rate of 25.2% (59). Among 
cCR patients with local regrowth, 97% of local regrowth 
was detected at the bowel wall while distant metastasis 
occurred in 8% of cCR patients. Based on this result, 
unsalvageable disease is rare even in cCR patients with later 
tumor regrowth (59). Therefore, this data support that a 
watch-and-wait strategy or deferred curative surgery can be 
performed as reasonable treatment options for cCR patients 
if an adequate clinical surveillance is guaranteed.
 
T2-Weighted Imaging 
Pathologic CR can be theoretically achieved in patients 
with mrTRG 1 and 2 (MERCURY classification) or complete 
normalization and fibrotic tissue (ESGAR classification) 
(Table 3). Clinical CR on T2-weighted MRI can be diagnosed 
when intermediate tumor signal disappears with or without 
fibrotic residues (Fig. 12). However, characterizing residual 
tumor with MRI is challenging because a distinction 
between fibrosis with and without residual tumors is 
difficult. Although a signal drop of the tumor on T2-
weighted image is widely accepted as a hallmark of CRT-
induced fibrosis, fibrosis frequently intermixes with viable 
tumor tissues and distinguishing these two components 
is often a difficult task (23). Furthermore, hyperintense 
Fig. 11. Positive EMVI on post-CRT MRI (ymrEMVI). 
A. Baseline MRI shows positive mrEMVI of grade 4 which indicates irregular vessels replaced by soft tissue with intermediate SI (arrow). B. Post-
CRT MRI still depicts positive ymrEMVI with minimal fibrotic change showing low SI (at least less than 25%) although prominent shrinkage is 
noted at primary rectal mass. EMVI = extramural venous invasion
A B
Table 3. MRI Findings Indicating pCR
Imaging Modality Imaging Findings Indicating pCR
T2-weighted imaging
- Complete normalization of rectal wall
- Dense fibrotic lesion with low SI similar to pelvic muscle without intermediate tumor SI
DWI No evidence of diffusion restriction within tumor 
T2 SI or DWI selective volumetry No viable tumor portion which shows lower SI than cut-off value*
*Cut-off values for predicting pCR have not yet been established. pCR = pathologic complete remission
1014
Seo et al.
https://doi.org/10.3348/kjr.2018.0611 kjronline.org
mucin on T2-weighted image makes the prediction of 
residual tumor viability more challenging (60). Intermingled 
tumor cells with fibrosis and the presence of mucin may be 
responsible for low level of agreement between mrTRG and 
pTRG, rendering mrTRG as an inappropriate surrogate for the 
prediction of pTRG (61). Indeed, the reported sensitivity 
and specificity for diagnosing pCR are 74.4% and 62.8%, 
respectively even in patients showing good response on 
post-CRT MRI (mrTRG 1 or 2) (61). 
MR Tumor Volumetry 
There have been several reports regarding the usefulness 
of MR volumetry for the prediction of tumor response 
after CRT (62, 63). In those studies, investigators used 
both quantitative SI and volume of the tumor in order to 
selectively measure the volume of viable tumor tissues on 
post-CRT MRI. They performed SI-selective volumetry with an 
exclusion of non-viable tissue components (fibrosis with low 
SI and mucin with high SI) using an intensity threshold. For 
example, pelvic muscle was used as an internal reference to 
define a threshold of fibrotic tissue. This approach seemed 
to improve the diagnostic performance of MRI for pCR 
assessment, compared with simple qualitative assessment or 
whole tumor volumetry (62, 63). 
Diffusion-Weighted Imaging 
Recently, DWI has been increasingly used and is routinely 
included in rectal MRI protocols (20). A few studies 
have reported encouraging results on DWI, describing 
its usefulness in aiding conventional MRI to improve the 
diagnostic accuracy for predicting pCR after CRT (Figs. 7, 
12) (64, 65). 
Even though DWI offers several benefits in various 
applications, it also has multiple possible shortcomings. 
For example, manual drawing of ROIs onto the tumor 
for quantitative or qualitative assessment may result in 
interobserver variation. Furthermore, image distortion due 
to artifacts is common on DWI, particularly around air-
tissue interfaces. During the restaging of tumor, radiologists 
tend to overestimate the presence of a tumor on T2-
weighted image alone. According to previous studies, such 
overestimation can be reduced when DWI was added on T2-
weighted image (64-66). In real clinical practice, however, 
such corrective effect of DWI may not be encountered 
because most conservative radiologists would not change 
their decision to cCR even in patients with no diffusion 
restriction on DWI if when residual tumor signal is present 
on T2-weighted imaging. 
According to a previous study, DWI volumetry without 
T2-weighted imaging showed highest AUC (> 0.90) for 
the assessment of pCR. This observation might be due to 
the fact that the bias related to T2-weighted imaging can 
be eliminated in this study (66). Another subsequent bi-
institutional independent validation study proved that the 
previously established cutoff value for DWI volumetry could 
be used to assess pCR after CRT accurately (15). Therefore, 
DWI volumetry may have some potential to overcome 
intrinsic limitations of qualitative DWI-related artifact or 
radiologists’ conservative tendency.
Combined Use of MRI and Colonoscopy
In the past, endoscopy and digital rectal exams served 
as the main tools for the assessment of treatment 
response (15, 67). Continuous decrease in tumor size and 
the disappearance of tumor tissues along with mucosal 
healing, were regarded as clinical signs of CR on endoscopy 
Fig. 12. Typical MRI findings of pathologic complete response after CRT. 
A. Baseline MRI (left) shows fungating tumor (arrow) with intermediate SI in lower rectum. DWI (right) demonstrates prominent diffusion 
restriction at tumor (arrow). B. Post-CRT MRI (left) reveals transmural fibrosis with dark SI in left lateral wall of rectum (arrow). There is no 
demonstrable residual tumor with intermediate SI. DWI (right) shows no evidence of diffusion restriction at corresponding tumor site.
A B
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(57). However, a major limitation of these techniques is 
that transmural or extraluminal tumor extent as well as 
mesorectum cannot be examined (57). Because residual 
tumors can present in any layer of the rectal wall regardless 
of tumor stage (57, 68, 69), MRI can reveal such residual 
tumors beneath the mucosa, which can be inaccessible via 
colonoscopy. 
Endoscopy and MRI may play a complementary role in 
rectal cancer restaging. Maas et al. (57) reported that the 
combined use of MRI and endoscopy resulted in a high PPV 
(98%). Although an improved PPV maximizes oncologic 
safety, it also decreases the opportunity of organ-preserving 
treatment in pCR patients with equivocal findings (57). 
However, we believe that such a conservative approach may 
be reasonable considering the limitation of imaging tools 
for predicting pCR after CRT and oncologic safety.
Selection of Candidates for Local Excision after 
Chemoradiotherapy 
Considering the limitations of MRI or endoscopy in 
predicting pCR, local excision may be a more go-ahead 
approach. Indeed, there have been conflicting arguments 
for the indications for local excision. Some reports have 
demonstrated acceptable oncologic outcomes after local 
excision for ypT2 lesions (42, 54, 70) while lymph node 
metastasis was reported in up to 20% of ypT2 lesions (38, 
71, 72). 
The most important issue in selecting patients for 
local excision is the guarantee of pN0 before an organ-
preserving treatment because lymph node removal is not 
performed and any residual viable tumor deposit may be 
left behind after local excision (42). Indeed, the risk for 
tumor recurrence after local excision has been described to 
parallel the risk of lymph node metastasis (2.0–9.1% for 
ypT0, 15.0–17.1% for ypT1, and 17.0–20.8% for ypT2) (38, 
71, 72). Therefore, an acceptable NPV for the presence of 
metastatic nodes is crucial for planning organ-preserving 
treatment. Even though the use of size criteria on post-CRT 
MRI shows a relatively high NPV (78–96%) (38, 70), such 
imperfect NPV does not entirely guarantee the oncologic 
safety after local excision. Therefore, the risk of local tumor 
recurrence due to residual metastatic lymph nodes should 
be compensated by strict MRI follow-up so as to facilitate 
early detection during the time window in which curative 
radical resection can still be performed (42). 
SUMMARY
Along with significant improvement in terms of treatment 
options and imaging tools, there is an increasing demand 
for reliable risk stratification after CRT for personalized 
tailored treatments in patients with LARC. Radiologists 
should be familiar with new surgical approaches. With 
the knowledge of oncologic concepts specific to rectal 
cancer management, radiologists should provide critical 
information during post-CRT MRI interpretation such as 
mrTRG, ycTN staging, relationship with anal sphincter 
complex, CRM status, and ymrEMVI. Post-CRT MRI may 
play a prominent role in the decision-making process for 
rectal cancer management. However, because current MRI 
techniques have several limitations for assessing treatment 
response after CRT, tumor response evaluation on post-
CRT MRI should be reliably or safely determined with an 
aid of DWI, MRI volumetry, and complementary endoscopy, 
balancing between oncologic safety and quality of life for 
patients.
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